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19th CardioVascular Summit: TCTAP 2014Conclusion: BVS absorb Everolimus eluting vascular scaffold showed favorable
clinical outcome without any major cardiac events (acute or late stent thrombosis, MI
or death) over a period of 9 month. Thus, BVS absorb would be favorable alternative
to other available drug eluting metallic stents.
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Background: With increasing complex PCI’s, long stents have been increasingly
used. However the long-term clinical outcomes of these stents have not been well
studied.
Methods: A retrospective analysis of 586 consecutive patients who underwent PCI
using paclitaxel DES (Taxus Liberté) during the period December 2005 to August
2007 was done. 90.1% were followed up for a median duration of 60 months (12- 86
months). Long stents were deﬁned as 28mm (group A)-178 patients (33.7%) were
compared to relative short stents 24mm (group B)-350 patients (66.3%).
Results: The study population was a high risk group with 43.3% diabetics in group A
and 46.3% in group B (p-0.524). other baseline characteristics were also well matched
except for inducible ischemia on treadmill which were more in group A 42.7% vs
group B 31.9% (p-0.012), patients in group A requiried more than one stent 50.6% vs
group B 37.7%(p –0.004) and patients in group A had more RCA interventions than
group B – 38.2% vs 25.7% (p-0.002). Mean no of stents implanted per patient was 1.5.
MACCE at hospital discharge was 0% in group A vs. 0.7% in group B (p – 0.557), at
1 year was 4.4% vs 4.3% (p-0.984), at 5 years was 12.8% vs 13.6% (p-0.871).TLR at
discharge was 0% in group A and 0.2% in group B (p-1.0), at 1 year was 3.1% vs
1.1% (p-0.138), at 5 years was signiﬁcantly higher in group A 4.9% vs 1.6% (p-
0.025).There is no difference in stent thrombosis at discharge 0% in group A vs.0.2%
group B (p-0.681), at 1 year 0.6% vs.1.6% (p-0.681), at 5 years was 0.6% vs 2.1% (p-
0.290). At 5 years, Deﬁnite ST was 0.6% in group A vs 0.3% group B (p-0.513),
Probable ST 0% vs 0.3% (p-1.0), Possible ST 0.6% vs 2.7% (p- 0.186). There was no
in hospital mortality in either groups, mortality at 1 year was 0% in group A vs 1.6%
in group B (p-0.185), at 5 years 2.5% vs 5.3% (p-0.175). The overall event-free
survival at 5 years was comparable in both the groups (87.2%vs.86.4%).
Conclusion: Clinical outcomes of long paclitaxel drug eluting stents ( 28 mm) were
comparable to relatively short stents ( 24mm) at 5 years.
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Background: The aim of this study is to compare clinical outcomes between 1st
generation sirolimus eluting stent and 2nd generation everolimus eluting stent in pa-
tients with diffuse long lesions for 2 years.
Methods: A total 381 Patients with diffuse long lesion treated with  50 mm stent
segment in de novo lesions from Jan 2006 to Aug 2011 were enrolled. The patients
were divided into two groups as sirolimus eluting stent (SES, n¼265) group and
everolimus eluting stent (EES, n¼116) group. Study end-points were major adverse
cardiac events (MACE) including all death, myocardial infarction (MI), and ischemic
driven target vessel revascularization (Id-TVR).
Results: Baseline characteristics were similar. Stent length was 61.711.0 in SES and
62.813.7 in EES (p¼0.593). For 2 years clinical follow-up, the rate of cumulative
MACE was 10.7% in SES and 7.4% in EES (p¼0.346). The rate of all death was
observed 5.7% in SES and 6.3% in EES group (p¼0.840). The rate of MI was
observed 2.3% in SES and 5.3% in EES (p¼0.153). The rate of Id-TVR was observed
7.7% in SES and 6.3% in EES (p¼0.666).
Conclusion: The clinical outcomes between SES and EES in patients with diffuse
long lesions were not different for 2 years. Further longer term follow-up and larger
population study will be needed for better evaluation.
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Background: Previous studies have demonstrated that patients with small coronary
artery lesions (SCAL) are at increased risk for late cardiac events after percutaneous
coronary intervention (PCI). It remains uncertain whether second-generation drug-
eluting stents have an advantage ﬁrst-generation drug-eluting stents (DES) in patients
with SCAL. This study aimed to evaluate the long-term efﬁcacy of everolimus-eluting
stent(EES) and sirolimus-eluting stents(SES) on SCAL.
Methods: Consecutive 353 patients with 400 SCAL, who were treated with EES (153
patients, 180 lesions) and SES (203 patients, 220 lesions) were enrolled. SCAL was
deﬁned the lesions with reference vessel diameter(RVD) <2.5 mm. Within ten months
angiographic follow-up results and 2-year clinical follow-up outcomes were compared
between EES and SES groups.
Results: The prevalence of diabetes was higher and the stent length was longer
(22.97.0 vs. 20.17.0, p<0.05) in EES group than in SES group. Initial success rate
was similar in both groups. There was no difference in 2-year %binary restenosis,
TLR (1.7vs. 4.7%), and MACE (3.3%vs 6.4%) rates between 2 groups. This similar
major adverse cardiovascular events rate remained after adjustment. However, the rate
of stent thrombosis was 0% in the EES group and 1.8% in the SES group (p ¼ 0.12).
Conclusion: EES demonstrated comparable clinical outcomes to those of SES in
SCAL. The absence of stent thrombosis among patients treated with EESs suggests a
good safety proﬁle for this second-generation drug-eluting stent, which should be
carefully studied in a larger series of patients with SCAL.
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Background: Nature of Coronary artery disease (CAD) in Bangladeshi population is
diffuse with small caliber arteries. Now a days, these are treated, by PCI with stent
deployment. However, long term data on In-stent re-stenosis (ISR) in these patients
are not yet available. Therefore, the aim of our present study was to assess long-term
outcome of stent patency or the development of ISR of varieties stent in single vessel
territory.
Methods: Patients were selected retrospectively, who underwent coronary angiogram
at our hospital for further evaluation of their previous PTCA in the 3->36 months
preceding the study for the quantifying period of 2006-2012. Total 577 patients (male:
474, Female: 103) were included in this study. Average age was Male: 56; Female: 59.
Average study period was 3.4.
Results: Our result shows that among the total studied population 82.1% (474) were
male and 17.9% (103) were female. Female were more obese than male BMI (27 vs
26). Total 864 stent were deployed in 785 vessels. Common stented territories were in
LAD 366 (46.6%), RCA 236 (30.1%) and LCX 183 (23.3%). Stent used were BMS
105(30.8%), DES 236 (69.2). Territory wise total number of deployed stent in LAD
396 (45.8%), RCA 272 (31.5%) and LCX 196 (22.7%. Single artery stent were done
in 442 (76.6%), double artery stent in 128 (22.2%) and Triple artery in 7 (1.2%)
patient. Total 94 (16.3%) patient had double/multiple stent in a single vessel territory.
Re-look Coronary Angiogram (CAG) revealed that the patency of stents in BMS 210
(56.5%) and DES 308 (73.5%) treated vessel. Signiﬁcant ISR (ISR>60%) developed
in BMS 97(26.1%) and DES 74 (17.6%). Among the different DES; patency in
Sirolimus 75.2% (157), Everolimus 70.7% (51), Paclitaxel 65.4% (71) and in Bio-
limus-A9 88.2% (15). Among the different DES the development of signiﬁcant ISR
were in Paclitaxel 20.4% (22), Sirolimus 18.6%(39), Everolimus 15.7%(11). Although
the other Biolimus
Conclusion: In our present prospective cohort, Sirolimus Eluting Stent shows better
patency with reduced ISR for an average period of 3.4 years.April 22–25, 2014 j TCTAP Abstracts/POSTER/Drug-eluting Stents
